Using PET Imaging to Evaluate Chemotherapy Response in GIST Patients
Author Information
Author(s): Stefanelli Antonella, Treglia Giorgio, Mirk Paoletta, Muoio Barbara, Giordano Alessandro
Primary Institution: Catholic University of the Sacred Heart
Hypothesis
Is 18F-FDG PET imaging a useful tool to evaluate treatment response to new chemotherapies beyond imatinib for GIST patients?
Conclusion
18F-FDG PET is effective in assessing therapy response earlier than CT imaging in GIST patients treated with agents beyond imatinib.
Supporting Evidence
- 18F-FDG PET can assess therapy response earlier than CT imaging.
- A dual modality PET-CT imaging is recommended for better detection of lesions.
- Imatinib resistance may lead to the need for alternative therapies in GIST patients.
Takeaway
Doctors use a special scan called PET to see how well new cancer treatments are working for patients with a type of tumor called GIST. This scan can show results faster than other methods.
Methodology
A literature review was performed on the role of 18F-FDG PET in evaluating treatment response to new chemotherapies for GIST patients.
Limitations
The review is limited by the small number of studies and patients evaluated.
Participant Demographics
GIST patients, often middle-aged and older, with varying responses to imatinib.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website